Ignite Creation Date:
2024-05-06 @ 7:36 AM
Last Modification Date:
2024-10-26 @ 11:50 AM
Study NCT ID:
NCT02560532
Status:
COMPLETED
Last Update Posted:
2018-07-10
First Post:
2015-09-23
Brief Title:
Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage
Sponsor:
Idorsia Pharmaceuticals Ltd
Organization:
Idorsia Pharmaceuticals Ltd
Study Overview
Official Title:
A Prospective Multi-center Open-label Single-arm Phase 2 Study to Assess the Efficacy and Safety of Clazosentan in Reversing Angiographically-confirmed Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage aSAH Treated by Surgical Clipping or Endovascular Coiling
Status:
COMPLETED
Status Verified Date:
2018-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REVERSE
Brief Summary:
The purpose of this study is to evaluate the safety and potential therapeutic benefit of use of clazosentan in reversing cerebral vasospasm a narrowing of blood vessels in the brain due to the presence of blood in the space around the brain in patients who have suffered a condition known as aneurysmal subarachnoid hemorrhage caused by bleeding onto the surface of the brain from a ruptured brain aneurysm
Detailed Description:
Aneurysmal subarachnoid hemorrhage aSAH is characterized by bleeding onto the brain surface due to a rupture of a pouch or bulge in a brain vessel called an aneurysm It is a rare but serious condition with a high risk of death Even patients who have had successful repair of the aneurysm remain at risk for developing cerebral vasospasm which can result in harmful conditions related to the lack of oxygen to parts of the brain and death Cerebral vasospasm usually occurs within the first couple of weeks after aSAH and it is difficult to treat Currently there is no safe efficacious and widely available treatment Previous animal studies have shown that a new drug under investigation clazosentan was able to reverse cerebral vasospasm in animal models of SAH A first trial conducted in a small number of patients showed some benefit of clazosentan in reversing established cerebral vasospasm after aSAH Clazosentan has already been evaluated in the prevention of cerebral vasospasm in several large clinical trials in aSAH This current study aims to evaluate if clazosentan is effective and safe in the treatment of cerebral vasospasm after aSAH
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2015-002721-18 | EUDRACT_NUMBER | None | None |